On September 4, 2015, the eighth subject was enrolled in our ongoing Israeli study of MDMA-assisted psychotherapy for PTSD. Led by Principal Investigator Moshe Kotler, M.D., this Phase 2 study will treat up to 10 subjects with chronic, treatment-resistant PTSD from any cause. "The preliminary results are encouraging, and enrollment has picked up late in the study due to increased recruitment efforts,” said Berra Yazar-Klosinski, Ph.D., MAPS Clinical Research Scientist. "This study is part of our efforts to reach participants where trauma is endemic.” This study is actively seeking Israeli participants.
